Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced/Metastatic Solid Tumors That Are MTAP Deficient

NCT06130553 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06130553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06130553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced/Metastatic Solid Tumors That Are MTAP Deficient
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 18, 2024
Completion date
December 4, 2028
Enrollment
334 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors that are mtap deficient